Baicalein Alleviates Neuropathic Pain by Inhibiting Microglial Activation and Inflammation Via the TLR4/NF-κB p65...

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Chronic neuropathic pain lacks effective treatments, with current options like opioids causing adverse effects.
• Baicalein (BA), a flavonoid from *Scutellaria baicalensis*, possesses anti-inflammatory properties and a history of safe use.
• Developing novel, safe therapies for neuropathic pain is a critical clinical need.

Purpose of the Study:

• To investigate the therapeutic efficacy of Baicalein (BA) in a preclinical model of neuropathic pain.
• To elucidate the underlying mechanisms of BA's action on pain pathways and neuroinflammation.

Main Methods:

• Utilized the spared nerve injury (SNI) model to induce neuropathic pain in rodents.
• Administered varying doses of BA to assess its impact on pain behaviors and molecular markers.
• Employed an in vitro microglial inflammation model to study BA's effects on cellular pathways.

Main Results:

• BA significantly alleviated SNI-induced hyperalgesia and chronic pain progression in a dose-dependent manner.
• BA inhibited glial cell activation, immune cell infiltration, and inflammatory responses in the injured nerve.
• In vitro, BA suppressed M1 microglial polarization and pro-inflammatory factor expression via the TLR4/NF-κB p65 pathway.

Conclusions:

• Baicalein demonstrates significant therapeutic potential for neuropathic pain.
• BA's mechanism involves the modulation of neuroinflammation and glial activation.
• BA represents a promising candidate for developing novel treatments for nerve injury-related pain.